Dr. Ron Epelbaum is currently the Director of the Division of Cancer in Rambam Health Care Campus (RHCC) in Haifa, Israel.
This comprehensive cancer center includes an Outpatient Clinic and Day-Care Unit which accepts about 30,000 visits of patients and delivers about 20,000 cancer treatments per year, the inpatient department contains 46 beds and a Radiotherapy Unit with 4 accelerators.
Dr. Epelbaum is a Clinical Associate Professor at the Faculty of Medicine of the Technion, the Israel Institute of Technology, in Haifa, Israel and a full-time cancer specialist at RHCC in Haifa. He obtained his degree as a senior oncologist in 1988 and completed his training as a Research Fellow for one year at Harvard University, in the Laboratory of Clinical Pharmacology at the Dana-Farber Cancer Institute, Boston, USA. His main research interest is treatment of pancreatic cancer and lymphoma, and he has been involved in many phase II-III trials exploring new therapies in these and other solid tumors.
Dr. Epelbaum is a member of several advisory committees in Israel and abroad, and is a member of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). He was an active member of the Early Clinical Study group (ECSG) of the European Organization for Research on Treatment of Cancer (EORTC). He took part in many early phase II and III trials conducted by this group, and chaired some of them. He has contributed to about 90 publications, including publications in the European Journal of Cancer, Blood, Cancer and Journal of Nuclear Medicine.